Table III.
Susceptibility profile of E. coli isolates studied to various antimicrobial agents.
| Antibiotics | Total UTI (n = 363) | CAUTI (n = 37) | non-CAUTI (n = 326) | OR (95% CI) | p-value | |||
|---|---|---|---|---|---|---|---|---|
| n’ | % susc. | n’ | % susc. | n’ | % susc. | |||
| Beta-lactam antibacterials, penicylinns | ||||||||
| Ampicillin | 354 | 30.2% | 36 | 19.4% | 318 | 31.4% | 0.53 (0.22–1.24) | 0.143 |
| AM/CL | 361 | 49.9% | 37 | 43.2% | 324 | 50.6% | 0.74 (0.37–1.48) | 0.397 |
| PIP/TZ | 207 | 87.0% | 19 | 68.4% | 188 | 88.8% | 0.27 (0.09–0.79) | 0.017 |
| Aminoglycosides | ||||||||
| Amikacin | 211 | 88.2% | 18 | 61.1% | 193 | 90.7% | 0.16 (0.06–0.47) | 0.001 |
| Gentamicin | 211 | 91.0% | 20 | 70.0% | 191 | 93.2% | 0.17 (0.06–0.52) | 0.002 |
| Cephalosporins | ||||||||
| Cefalexin | 197 | 79.7% | 17 | 41.2% | 180 | 83.3% | 0.14 (0.05–0.40) | < 0.001 |
| Cefuroxime | 358 | 85.8% | 36 | 75.0% | 322 | 87.0% | 0.45 (0.20–1.02) | 0.057 |
| Cefotaxime | 238 | 87.0% | 22 | 63.6% | 216 | 89.4% | 0.21 (0.08–0.55) | 0.002 |
| Ceftazidime | 237 | 83.5% | 21 | 61.9% | 216 | 85.6% | 0.27 (0.10–0.71) | 0.008 |
| Cefepime | 210 | 89.5% | 19 | 73.7% | 191 | 91.1% | 0.27 (0.09–0.85) | 0.025 |
| Antipseudomonal fluoroquinolones | ||||||||
| Ciprofloxacin | 361 | 70.4% | 37 | 54.1% | 324 | 72.2% | 0.45 (0.23–0.90) | 0.024 |
| Norfloxacin | 360 | 60.3% | 37 | 40.5% | 323 | 62.5% | 0.41 (0.20–0.82) | 0.011 |
| Folate pathway inhibitors | ||||||||
| Cotrimoxazole | 358 | 72.3% | 36 | 72.2% | 322 | 72.4% | 0.99 (0.46–2.14) | 0.986 |
| Antipseudomonal carbapenems | ||||||||
| Imipenem | 179 | 100.0% | 18 | 100.0% | 161 | 100.0% | – | – |
| Nitrofuran derivatives | ||||||||
| Nitrofurantoin | 357 | 89.4% | 37 | 83.8% | 320 | 90.0% | 0.57 (0.22–1.48) | 0.251 |
Abbrevations: Amoxicillin/clavulanic acid = AM/CL, Piperacillin/Tazobactam = PIP/TZ
n’ – number of all determinations for a given antibiotic; % susc. – % susceptibility